{"id":7306,"date":"2020-01-14T16:59:10","date_gmt":"2020-01-14T11:29:10","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7306"},"modified":"2023-06-14T17:03:40","modified_gmt":"2023-06-14T11:33:40","slug":"recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer","title":{"rendered":"Eli Lilly to acquire Dermira, Boehringer buys Enleofen\u2019s IL-11 platform, Biogen acquires Pfizer\u2019s Alzheimer\u2019s drug"},"content":{"rendered":"\n

Eli Lilly has announced to buy a biopharmaceutical company, Dermira, for a whopping sum of USD 1.1 Billion in an all-cash transaction. <\/strong><\/h3>\n\n\n\n

Through the acquisition, Eli Lilly is planning to expand its immunology pipeline by adding lebrikizumab<\/strong>, which is a novel, investigational, monoclonal antibody. The drug is designed to bind IL-13 with high affinity and is under Phase 3 clinical development trial for the treatment of moderate-to-severe atopic dermatitis<\/a><\/strong> in adolescent and adult patients, ages 12 years and older. The USFDA had already given the drug Fast Track designation last month.<\/p>\n\n\n\n

So far, the only approved therapy that targets the IL-4\/13 pathway is Dupilumab<\/a><\/strong>, a joint product of Regeneron Pharmaceuticals and Sanofi.<\/p>\n\n\n\n

In addition to lebrikizumab, Lilly will also get its hands on QBREXZA<\/strong> (glycopyrronium), an FDA-approved medicated cloth as a topical therapy for primary axillary hyperhidrosis<\/a><\/strong>. <\/p>\n\n\n\n

Many other companies like Eli Lilly are developing therapies to advance derma market and address unmet needs. <\/p>\n\n\n\n

Boehringer Ingelheim has announced the acquisition of Enleofen Bio\u2019s interleukin-11 (IL-11) platform to fuel the fibro-inflammatory disease treatment market. <\/strong><\/h3>\n\n\n\n

Inteleukin-11 (IL-11) is a cytokine that uses the cells of the body to communicate within the other parts and has been held responsible for causing diseases of liver, kidneys, lungs and as severe as cancer.  Inhibiting the overexpression of IL-11 is associated with the prevention of fibrosis, inflammation and helps in restoring the organ function. <\/p>\n\n\n\n

Enleofen\u2019s preclinical interleukin-11 (IL-11) platform has expertise in developing first-in-class therapies across a spectrum of fibro-inflammatory disorders. <\/p>\n\n\n\n

The agreement will help Boehringer to gain exclusive rights to the platform, thus adding concrete to the existing strong therapeutic pipeline. <\/p>\n\n\n\n

Under the terms, Enleofen would be eligible to receive around 1 Billion USD per product in upfront and upon achieving developmental and commercial milestones. <\/p>\n\n\n\n

Biogen, in a recent move to build its Alzheimer\u2019s pipeline strong, has acquired Pfizer\u2019s experimental drug for USD 75 Million in an upfront deal. <\/strong><\/h3>\n\n\n\n

The drug candidate PF-05251749, a CK1 inhibitor has the potential to treat sundowning in Alzheimer\u2019s<\/a> and irregular sleep-wake rhythm disorder (ISWRD) in Parkinson\u2019s disease. The ability of the drug to cross the blood-brain barrier and regulate circadian rhythms helps in improving behavioural and neurological symptoms in Alzheimer\u2019s<\/a> patients.\u00a0<\/p>\n\n\n\n

Moreover, the agreement also enables Pfizer to receive an amount of USD 635 Million in milestone payments. <\/p>\n\n\n\n

A few months back, the decision of Biogen to resurrect its drug Aducanumab shocked many. But it seems, the company is hell-bent in bringing its drug in the market. The recent acquisition reinforces the gamble Biogen has played to find a cure for Alzheimer\u2019s.
<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly has announced to buy a biopharmaceutical company, Dermira, for a whopping sum of USD 1.1 Billion in an all-cash transaction. Through the acquisition, Eli Lilly is planning to expand its immunology pipeline by adding lebrikizumab, which is a novel, investigational, monoclonal antibody. The drug is designed to bind IL-13 with high affinity and […]<\/p>\n","protected":false},"author":1,"featured_media":7307,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17960,830,17289,17959,228,349,460,639,5789],"industry":[17225],"therapeutic_areas":[17227,17245],"class_list":["post-7306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers-disease-pipeline","tag-biogen","tag-boehringer-ingelheim","tag-dermira","tag-eli-lilly","tag-latest-pharma-news","tag-pfizer","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-neurology"],"acf":[],"yoast_head":"\nEli Lilly acquires Dermira, Boehringer buys Enleofen\u2019s IL-11 platform<\/title>\n<meta name=\"description\" content=\"The drug candidate PF-05251749, a CK1 inhibitor has the potential to treat sundowning in Alzheimer\u2019s and ISWRD in Parkinson\u2019s disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly acquires Dermira, Boehringer buys Enleofen\u2019s IL-11 platform\" \/>\n<meta property=\"og:description\" content=\"The drug candidate PF-05251749, a CK1 inhibitor has the potential to treat sundowning in Alzheimer\u2019s and ISWRD in Parkinson\u2019s disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-14T11:29:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T11:33:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/14165651\/PHARMA_NEWS_14.01.2020.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly acquires Dermira, Boehringer buys Enleofen\u2019s IL-11 platform","description":"The drug candidate PF-05251749, a CK1 inhibitor has the potential to treat sundowning in Alzheimer\u2019s and ISWRD in Parkinson\u2019s disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly acquires Dermira, Boehringer buys Enleofen\u2019s IL-11 platform","og_description":"The drug candidate PF-05251749, a CK1 inhibitor has the potential to treat sundowning in Alzheimer\u2019s and ISWRD in Parkinson\u2019s disease.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-01-14T11:29:10+00:00","article_modified_time":"2023-06-14T11:33:40+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/14165651\/PHARMA_NEWS_14.01.2020.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer","name":"Eli Lilly acquires Dermira, Boehringer buys Enleofen\u2019s IL-11 platform","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/14165651\/PHARMA_NEWS_14.01.2020.jpg","datePublished":"2020-01-14T11:29:10+00:00","dateModified":"2023-06-14T11:33:40+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The drug candidate PF-05251749, a CK1 inhibitor has the potential to treat sundowning in Alzheimer\u2019s and ISWRD in Parkinson\u2019s disease.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-eli-lilly-dermira-biogen-pfizer-boehringer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/14165651\/PHARMA_NEWS_14.01.2020.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/14165651\/PHARMA_NEWS_14.01.2020.jpg","width":772,"height":482,"caption":"pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/14165651\/PHARMA_NEWS_14.01.2020-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Boehringer Ingelheim<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dermira<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u0092s Disease Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Biogen<\/span>","<span class=\"advgb-post-tax-term\">Boehringer Ingelheim<\/span>","<span class=\"advgb-post-tax-term\">Dermira<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jan 14, 2020","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Jan 14, 2020 4:59 pm","modified":"Updated on Jun 14, 2023 5:03 pm"},"featured_img_caption":"pharma news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7306"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7306\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7307"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7306"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7306"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}